Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial

Conditions:   Clinical Stage III Merkel Cell Carcinoma AJCC v8;   Clinical Stage IV Merkel Cell Carcinoma AJCC v8;   Locally Advanced Merkel Cell Carcinoma;   Metastatic Merkel Cell Carcinoma;   Refractory Merkel Cell Carcinoma;   Unresectable Merkel Cell Carcinoma Interventions:   Drug: Avelumab;   Procedure: Biopsy;   Procedure: Biospecimen Collection;   Procedure: Computed Tomography;   Procedure: Magnetic Resonance Imaging;   Procedure: Positron Emission Tomography;   Drug: Tuvusertib Sponsor:   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials